Personalized 1st-line Treatment of Patients With NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in a Routine Practice Setting in Antwerp.
The favourable results of a number of phase III-trials with gefitinib in NSCLC patients with
activating EGFR-mutations, have resulted in the licensing of gefitinib in this indication.
This offers the prospect of a true personalized treatment of patients with NSCLC.
Implementation of such a personalized treatment strategy is dependent both on the
availability of adequate tumor samples for the EGFR-mutation analysis and on the timely
reporting of the mutation analysis results. Ideally the results should be available in all
patients within 2 weeks of the analysis request.
Observational Model: Case-Only, Time Perspective: Prospective
testing turn around time (in days)
how long does it take to get the mutation analysis result
up to 1 month
Paul R Germonpre, MD
UZA + Thoracale Oncologie Groep Antwerpen
Belgium: Institutional Review Board